Loading
A phase 3 trial of Nilotinib, Ceritinib, Capmatinib, Lapatinib, Trametinib, Olaparib, Palbociclib and Glasdegib in Sarcomas, run by Institut National de la Santé Et de la Recherche Médicale, France, completed.
Molecular Profiling of Advanced Soft-tissue Sarcomas is a phase 3 interventional study registered as NCT03784014 by Institut National de la Santé Et de la Recherche Médicale, France, with 603 participants recorded, started 2019-10-19 and reaching its primary completion in 2023-12-01. Interventions recorded: Nilotinib, Ceritinib, Capmatinib, Lapatinib, Trametinib, Trametinib and Dabrafenib, Olaparib and Durvalumab, Palbociclib, Glasdegib, TAS-120, Next Generation sequencing exome. Conditions recorded: Soft Tissue Sarcoma.
Linked to the drug Ceritinib because the registry names it among its interventions and Sarcomas among its conditions. Registry record only: no result has been read by an editor.
Shares Glasdegib and the tag pipeline.
Shares Glasdegib and the tag pipeline.
Shares Lapatinib and the tag pipeline.
Shares Glasdegib and the tag pipeline.
Shares Ceritinib and the tag pipeline.
Shares Capmatinib and the tag pipeline.
Shares Capmatinib and the tag pipeline.
Shares Capmatinib and the tag pipeline.